JP2015513533A5 - - Google Patents

Download PDF

Info

Publication number
JP2015513533A5
JP2015513533A5 JP2014557802A JP2014557802A JP2015513533A5 JP 2015513533 A5 JP2015513533 A5 JP 2015513533A5 JP 2014557802 A JP2014557802 A JP 2014557802A JP 2014557802 A JP2014557802 A JP 2014557802A JP 2015513533 A5 JP2015513533 A5 JP 2015513533A5
Authority
JP
Japan
Prior art keywords
szeto
schiller
phe
lys
arg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014557802A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015513533A (ja
JP6356614B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/026299 external-priority patent/WO2013123298A1/en
Publication of JP2015513533A publication Critical patent/JP2015513533A/ja
Publication of JP2015513533A5 publication Critical patent/JP2015513533A5/ja
Application granted granted Critical
Publication of JP6356614B2 publication Critical patent/JP6356614B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014557802A 2012-02-17 2013-02-15 薬剤のミトコンドリア輸送のためのナノ粒子 Expired - Fee Related JP6356614B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261600088P 2012-02-17 2012-02-17
US61/600,088 2012-02-17
PCT/US2013/026299 WO2013123298A1 (en) 2012-02-17 2013-02-15 Nanoparticles for mitochondrial trafficking of agents

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018008528A Division JP6612905B2 (ja) 2012-02-17 2018-01-23 薬剤のミトコンドリア輸送のためのナノ粒子

Publications (3)

Publication Number Publication Date
JP2015513533A JP2015513533A (ja) 2015-05-14
JP2015513533A5 true JP2015513533A5 (enExample) 2015-10-08
JP6356614B2 JP6356614B2 (ja) 2018-07-11

Family

ID=48984733

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2014557802A Expired - Fee Related JP6356614B2 (ja) 2012-02-17 2013-02-15 薬剤のミトコンドリア輸送のためのナノ粒子
JP2018008528A Expired - Fee Related JP6612905B2 (ja) 2012-02-17 2018-01-23 薬剤のミトコンドリア輸送のためのナノ粒子
JP2019198467A Expired - Fee Related JP6904606B2 (ja) 2012-02-17 2019-10-31 薬剤のミトコンドリア輸送のためのナノ粒子

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2018008528A Expired - Fee Related JP6612905B2 (ja) 2012-02-17 2018-01-23 薬剤のミトコンドリア輸送のためのナノ粒子
JP2019198467A Expired - Fee Related JP6904606B2 (ja) 2012-02-17 2019-10-31 薬剤のミトコンドリア輸送のためのナノ粒子

Country Status (5)

Country Link
US (2) US10416167B2 (enExample)
EP (1) EP2814496B1 (enExample)
JP (3) JP6356614B2 (enExample)
ES (1) ES2669561T3 (enExample)
WO (1) WO2013123298A1 (enExample)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2750662A4 (en) 2011-08-31 2015-06-24 Univ Georgia NANOPARTICLES OBTAINING APOPTOSIS
JP6356614B2 (ja) 2012-02-17 2018-07-11 ユニバーシティ・オブ・ジョージア・リサーチ・ファウンデイション・インコーポレイテッド 薬剤のミトコンドリア輸送のためのナノ粒子
EP2971010B1 (en) 2013-03-14 2020-06-10 ModernaTX, Inc. Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
EP3041938A1 (en) 2013-09-03 2016-07-13 Moderna Therapeutics, Inc. Circular polynucleotides
JP2016530294A (ja) 2013-09-03 2016-09-29 モデルナ セラピューティクス インコーポレイテッドModerna Therapeutics,Inc. キメラポリヌクレオチド
KR20160067219A (ko) 2013-10-03 2016-06-13 모더나 세라퓨틱스, 인코포레이티드 저밀도 지단백질 수용체를 암호화하는 폴리뉴클레오타이드
EP3080137A4 (en) 2013-12-12 2017-07-19 The University Of Georgia Research Foundation, Inc Prodrug for release of cisplatin and cyclooxygenase inhibitor
WO2015123576A2 (en) * 2014-02-17 2015-08-20 The Brigham And Women's Hospital, Inc. Targeted nanoparticle compositions and methods of their use to treat obesity
US10398663B2 (en) 2014-03-14 2019-09-03 University Of Georgia Research Foundation, Inc. Mitochondrial delivery of 3-bromopyruvate
EP3142964B1 (en) * 2014-05-13 2021-12-22 B.G. Negev Technologies and Applications Ltd., at Ben-Gurion University Peptide-polypeptide co-assembled nanoparticles for drug delivery
WO2016014846A1 (en) 2014-07-23 2016-01-28 Moderna Therapeutics, Inc. Modified polynucleotides for the production of intrabodies
US10272088B2 (en) * 2014-07-25 2019-04-30 Wake Forest University Health Sciences FAS inhibitors and methods associated therewith
JP2017530941A (ja) * 2014-08-04 2017-10-19 ユニバーシティ・オブ・ジョージア・リサーチ・ファウンデイション・インコーポレイテッド 脳内に蓄積する治療用ナノ粒子
US10450289B2 (en) 2015-06-08 2019-10-22 University of Pittsburgh—of the Commonwealth System of Higher Education Substituted β-lapachones for treating cancer
WO2017095751A1 (en) * 2015-12-02 2017-06-08 Partikula Llc Compositions and methods for modulating cancer cell metabolism
US20180011346A1 (en) * 2016-07-05 2018-01-11 Nanoco Technologies Ltd. Probe for targeting and manipulating mitochondrial function using quantum dots
WO2018071761A1 (en) 2016-10-13 2018-04-19 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Mitochondrially targeted parp inhibitor, and uses thereof
JP7285220B2 (ja) 2017-05-18 2023-06-01 モデルナティエックス インコーポレイテッド 連結したインターロイキン-12(il12)ポリペプチドをコードするポリヌクレオチドを含む脂質ナノ粒子
EP4253544A3 (en) 2017-05-18 2023-12-20 ModernaTX, Inc. Modified messenger rna comprising functional rna elements
MA49395A (fr) 2017-06-14 2020-04-22 Modernatx Inc Polynucléotides codant pour le facteur viii de coagulation
MA50803A (fr) 2017-11-22 2020-09-30 Modernatx Inc Polynucléotides codant pour l'ornithine transcarbamylase pour le traitement de troubles du cycle de l'urée
JP7424976B2 (ja) 2017-11-22 2024-01-30 モダーナティエックス・インコーポレイテッド プロピオン酸血症の治療用のプロピオニルCoAカルボキシラーゼアルファ及びベータサブユニットをコードするポリヌクレオチド
EP3714047A2 (en) 2017-11-22 2020-09-30 ModernaTX, Inc. Polynucleotides encoding phenylalanine hydroxylase for the treatment of phenylketonuria
MA51523A (fr) 2018-01-05 2020-11-11 Modernatx Inc Polynucléotides codant pour des anticorps anti-virus du chikungunya
WO2019226650A1 (en) 2018-05-23 2019-11-28 Modernatx, Inc. Delivery of dna
WO2020014253A1 (en) * 2018-07-10 2020-01-16 The Board Of Trustees Of The Leland Stanford Junior University Fluorescent nanoparticles and imaging uses
US20220184185A1 (en) 2018-07-25 2022-06-16 Modernatx, Inc. Mrna based enzyme replacement therapy combined with a pharmacological chaperone for the treatment of lysosomal storage disorders
MA53545A (fr) 2018-09-02 2021-07-14 Modernatx Inc Polynucléotides codant pour l'acyl-coa déshydrogénase à très longue chaîne pour le traitement de l'insuffisance en acyl-coa déshydrogénase à très longue chaîne
US20230009009A1 (en) 2018-09-13 2023-01-12 Modernatx, Inc. Polynucleotides encoding glucose-6-phosphatase for the treatment of glycogen storage disease
WO2020056155A2 (en) 2018-09-13 2020-03-19 Modernatx, Inc. Polynucleotides encoding branched-chain alpha-ketoacid dehydrogenase complex e1-alpha, e1-beta, and e2 subunits for the treatment of maple syrup urine disease
EP3850102A1 (en) 2018-09-14 2021-07-21 ModernaTX, Inc. Polynucleotides encoding uridine diphosphate glycosyltransferase 1 family, polypeptide a1 for the treatment of crigler-najjar syndrome
US20220152225A1 (en) 2018-09-27 2022-05-19 Modernatx, Inc. Polynucleotides encoding arginase 1 for the treatment of arginase deficiency
KR102104068B1 (ko) * 2018-12-19 2020-04-23 가톨릭대학교 산학협력단 미토콘드리아 표적능을 갖는 고분자 및 상기 고분자를 이용한 약물 전달용 조성물
EP3965797A1 (en) 2019-05-08 2022-03-16 AstraZeneca AB Compositions for skin and wounds and methods of use thereof
AU2021285812A1 (en) 2020-06-01 2023-01-05 Modernatx, Inc. Phenylalanine hydroxylase variants and uses thereof
WO2022104131A1 (en) 2020-11-13 2022-05-19 Modernatx, Inc. Polynucleotides encoding cystic fibrosis transmembrane conductance regulator for the treatment of cystic fibrosis
EP4314260A1 (en) 2021-03-24 2024-02-07 Modernatx, Inc. Lipid nanoparticles and polynucleotides encoding ornithine transcarbamylase for the treatment of ornithine transcarbamylase deficiency
US20240207444A1 (en) 2021-03-24 2024-06-27 Modernatx, Inc. Lipid nanoparticles containing polynucleotides encoding phenylalanine hydroxylase and uses thereof
US20240216288A1 (en) 2021-03-24 2024-07-04 Modernatx, Inc. Lipid nanoparticles containing polynucleotides encoding propionyl-coa carboxylase alpha and beta subunits and uses thereof
WO2022204369A1 (en) 2021-03-24 2022-09-29 Modernatx, Inc. Polynucleotides encoding methylmalonyl-coa mutase for the treatment of methylmalonic acidemia
WO2022204371A1 (en) 2021-03-24 2022-09-29 Modernatx, Inc. Lipid nanoparticles containing polynucleotides encoding glucose-6-phosphatase and uses thereof
US20220370636A1 (en) * 2021-05-05 2022-11-24 University Of South Florida Nicotinamide adenine dinucleotide activator and use thereof
US20240384277A1 (en) 2021-06-15 2024-11-21 Modernatx, Inc. Engineered polynucleotides for cell-type or microenvironment-specific expression
WO2022271776A1 (en) 2021-06-22 2022-12-29 Modernatx, Inc. Polynucleotides encoding uridine diphosphate glycosyltransferase 1 family, polypeptide a1 for the treatment of crigler-najjar syndrome
US20250017867A1 (en) 2021-10-01 2025-01-16 Modernatx, Inc. Polynucleotides encoding relaxin for the treatment of fibrosis and/or cardiovascular disease
WO2023183909A2 (en) 2022-03-25 2023-09-28 Modernatx, Inc. Polynucleotides encoding fanconi anemia, complementation group proteins for the treatment of fanconi anemia
CN114904005B (zh) * 2022-05-24 2024-02-02 浙江大学医学院附属第一医院 一种低密度三苯基膦修饰的体内长循环药物制剂及其制备方法和应用
MA71619A (fr) 2022-07-26 2025-05-30 Modernatx, Inc. Polynucléotides modifiés pour la régulation temporelle de l'expression
WO2024197033A1 (en) 2023-03-21 2024-09-26 Modernatx, Inc. Polynucleotides encoding relaxin for the treatment of heart failure
AU2024265267A1 (en) 2023-05-03 2025-11-20 Modernatx, Inc. Polynucleotides encoding cystic fibrosis transmembrane conductance regulator for the treatment of cystic fibrosis
WO2025072482A1 (en) 2023-09-27 2025-04-03 Modernatx, Inc. Immunoglobulin a protease polypeptides, polynucleotides, and uses thereof
WO2025255199A1 (en) 2024-06-05 2025-12-11 Modernatx, Inc. Argininosuccinate synthase 1 and argininosuccinate lyase polypeptides and polynucleotides and uses thereof

Family Cites Families (138)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6217864B1 (en) 1996-02-23 2001-04-17 The Regents Of The University Of California Method for targeted degradation of intracellular proteins in vivo or ex vivo
US6048736A (en) 1998-04-29 2000-04-11 Kosak; Kenneth M. Cyclodextrin polymers for carrying and releasing drugs
WO2000000503A1 (en) 1998-06-26 2000-01-06 The Regents Of The University Of California Human az-1 gene, variants thereof and expressed gene products
US6753154B1 (en) 1998-06-26 2004-06-22 The Regents Of The University Of California Human AZU-1 gene, variants thereof and expressed gene products
US20050153913A1 (en) 2001-04-10 2005-07-14 Kosak Kenneth M. Nucleic acid carrier compositions and methods for their synthesis
US20040038303A1 (en) 2002-04-08 2004-02-26 Unger Gretchen M. Biologic modulations with nanoparticles
AU2003251397B2 (en) 2002-06-05 2009-10-01 Genentech, Inc. Compositions and methods for liver growth and liver protection
CA2523413A1 (en) 2003-04-25 2004-11-11 The Penn State Research Foundation Method and system for systemic delivery of growth arresting, lipid-derived bioactive compounds
US7329638B2 (en) 2003-04-30 2008-02-12 The Regents Of The University Of Michigan Drug delivery compositions
US7728036B2 (en) 2003-05-20 2010-06-01 Erimos Pharmaceuticals, Llc Methods for delivery of catecholic butanes for treatment of tumors
RU2487880C2 (ru) 2003-08-22 2013-07-20 Антиподин Фармасьютикалз Инк. Направленно вводимые в митохондрии производные убихинона в качестве антиоксидантов для снижения окислительного стресса, фармацевтическая композиция, способ получения, способ лечения
ES2541769T3 (es) * 2003-08-22 2015-07-24 Antipodean Pharmaceuticals, Inc. Derivados de mitoquinona usados como antioxidantes dirigidos a las mitocondrias
WO2005058028A2 (en) 2003-12-16 2005-06-30 Genentech, Inc. Novel gene disruptions, compositions and methods relating thereto
US7393924B2 (en) 2004-01-06 2008-07-01 Franco Vitaliano Smart bio-nanoparticle elements
WO2005079566A2 (en) 2004-02-12 2005-09-01 Lexicon Genetics Incorporated Gene disruptions, compositions and methods relating thereto
US20100031378A1 (en) 2008-08-04 2010-02-04 Edwards Joel A Novel gene disruptions, compositions and methods relating thereto
US8128908B2 (en) 2004-04-30 2012-03-06 University Of Florida Research Foundation, Inc. Nanoparticles and their use for multifunctional bioimaging
CA2562482A1 (en) 2004-05-12 2005-12-01 Genentech, Inc. Novel gene disruptions, compositions and methods relating thereto
US20060040879A1 (en) 2004-08-21 2006-02-23 Kosak Kenneth M Chloroquine coupled nucleic acids and methods for their synthesis
US20070166281A1 (en) 2004-08-21 2007-07-19 Kosak Kenneth M Chloroquine coupled antibodies and other proteins with methods for their synthesis
WO2007040469A2 (en) 2005-09-15 2007-04-12 Kosak Ken M Chloroquine coupled compositions and methods for their synthesis
US20080051323A1 (en) 2004-08-21 2008-02-28 Kosak Kenneth M Chloroquine drug compositions and methods for their synthesis
EP1781824A2 (en) 2004-08-25 2007-05-09 Genentech, Inc. Novel gene disruptions, compositions and methods relating thereto
ZA200704338B (en) 2004-10-29 2009-03-25 Genentech Inc Novel gene disruptions, compositions and methods relating thereto
FR2877571B1 (fr) * 2004-11-05 2007-04-13 Nanobiotix Sarl Nanoparticules pourvues d'un element de ciblage intracellulaire, preparation et utilisations
EP1838353A2 (en) 2005-01-21 2007-10-03 Introgen Therapeutics, Inc. Topical administration permitting prolonged exposure of target cells to therapeutic and prophylactic nucleic acids
CN101146826A (zh) 2005-01-24 2008-03-19 得克萨斯大学体系董事会 与磷脂酰丝氨酸结合的fc融合构建体及其治疗用途
ATE452120T1 (de) 2005-01-27 2010-01-15 Ocean Nutrition Canada Ltd Fettsäure-benzenediol-derivate sowie herstellungs-und verwendungsverfahren dafür
US20110097330A1 (en) 2005-03-11 2011-04-28 Genentech, Inc. Novel Gene Disruptions, Compostitions and Methods Relating Thereto
US20070014833A1 (en) 2005-03-30 2007-01-18 Sirtris Pharmaceuticals, Inc. Treatment of eye disorders with sirtuin modulators
US7638558B2 (en) 2005-04-01 2009-12-29 Intezyne Technologies, Inc. Polymeric micelles for drug delivery
US7725169B2 (en) 2005-04-15 2010-05-25 The Board Of Trustees Of The University Of Illinois Contrast enhanced spectroscopic optical coherence tomography
US20060292099A1 (en) 2005-05-25 2006-12-28 Michael Milburn Treatment of eye disorders with sirtuin modulators
CA2609549A1 (en) 2005-05-25 2006-11-30 Sirtris Pharmaceuticals, Inc. Treatment of eye disorders with sirtuin modulators
US20090214618A1 (en) 2005-05-27 2009-08-27 Schoenfisch Mark H Nitric oxide-releasing particles for nitric oxide therapeutics and biomedical applications
WO2006132788A2 (en) 2005-06-06 2006-12-14 Genentech, Inc. Transgenic models for different genes and their use for gene characterization
US20060286082A1 (en) 2005-06-20 2006-12-21 Kurzweil Raymond C Systems and methods for generating biological material
WO2008054341A2 (en) 2005-06-20 2008-05-08 The Research Foundation Of State University Of New York Method of bioimaging using nanocrystals of fluorescent dyes
KR20080031474A (ko) 2005-07-27 2008-04-08 유니버시티 오브 플로리다 리서치 파운데이션, 아이엔씨. 안구 질환의 치료를 위한 열충격의 사용
AU2006280321A1 (en) 2005-08-15 2007-02-22 Genentech, Inc. Gene disruptions, compositions and methods relating thereto
WO2007033215A2 (en) 2005-09-12 2007-03-22 The Johns Hopkins University Compositions having antiangiogenic activity and uses thereof
US20090022806A1 (en) 2006-12-22 2009-01-22 Mousa Shaker A Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists and formulations and uses thereof
WO2008048288A2 (en) 2005-11-09 2008-04-24 Montana State University Novel nanoparticles and use thereof
CA2630432A1 (en) 2005-11-21 2007-07-19 Genentech, Inc. Novel gene disruptions, compositions and methods relating thereto
US20110172826A1 (en) 2005-12-14 2011-07-14 Amodei Dario G Device including altered microorganisms, and methods and systems of use
US8682619B2 (en) 2005-12-14 2014-03-25 The Invention Science Fund I, Llc Device including altered microorganisms, and methods and systems of use
US8241902B2 (en) 2006-01-11 2012-08-14 Technion Research & Development Foundation Ltd. Preparation of adult stem cell-derived connective tissue progenitors
US20080311107A1 (en) 2006-02-17 2008-12-18 Genetech, Inc. Novel Gene Disruptions, Compositions and Methods Relating Thereto
WO2007101111A2 (en) 2006-02-23 2007-09-07 Erimos Pharmaceuticals Llc Methods of treating influenza viral infections
EP2018186A2 (en) 2006-04-11 2009-01-28 Ordway Research Institute, Inc. Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations thereof
JP2009533455A (ja) 2006-04-12 2009-09-17 マサチューセッツ インスティテュート オブ テクノロジー 癒着を阻害するための組成物および方法
US8449915B1 (en) * 2006-04-17 2013-05-28 Gp Medical, Inc. Pharmaceutical composition of nanoparticles
EP2082645A1 (en) 2006-04-19 2009-07-29 Genentech, Inc. Novel gene disruptions, compositions and methods relating thereto
US20080187487A1 (en) 2006-05-03 2008-08-07 Gustavo Larsen Methods for producing multilayered particles, fibers and sprays and methods for administering the same
US7671095B2 (en) 2006-05-31 2010-03-02 The Trustees Of The Boston University Films and particles
EP2032623A2 (en) 2006-05-31 2009-03-11 The Trustees of the Boston University Films and particles
CA2654593A1 (en) 2006-06-08 2007-12-13 Bayer Schering Pharma Aktiengesellschaft Functionalized, solid polymer nanoparticles for diagnostic and therapeutic applications
US8501478B2 (en) 2006-06-15 2013-08-06 University Of Cincinnati Trehalose click polymers for delivery of biologically active molecules
US8465775B2 (en) 2006-07-27 2013-06-18 The University Of North Carolina At Chapel Hill Nanoparticle fabrication methods, systems, and materials for fabricating artificial red blood cells
EP2046965A2 (en) 2006-07-28 2009-04-15 Genentech, Inc. Knockout mice for different genes and their use for gene characterization
EP2610244A1 (en) 2006-08-07 2013-07-03 Ironwood Pharmaceuticals, Inc. Indole compounds
WO2008042896A2 (en) 2006-10-02 2008-04-10 Erimos Pharmaceuticals Llc Tetra-substituted ndga derivatives via ether bonds and carbamate bonds and their synthesis and pharmaceutical use
AU2007351501A1 (en) 2006-11-14 2008-10-23 Genentech, Inc. Novel gene disruptions, compositions and methods relating thereto
WO2008091465A2 (en) 2006-12-21 2008-07-31 Wayne State University Peg and targeting ligands on nanoparticle surface
CA2673133C (en) 2006-12-22 2016-08-30 Clf Medical Technology Acceleration Program, Inc. Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations and uses thereof
WO2008085828A2 (en) 2007-01-03 2008-07-17 The Johns Hopkins University Peptide modulators of angiogenesis and use thereof
EP2114141A2 (en) 2007-01-10 2009-11-11 University of Florida Compounds and methods for treatment of alpha-1 antitrypsin deficiency
CA2676323A1 (en) 2007-01-18 2008-07-24 Suomen Punainen Risti, Veripalvelu Novel methods and reagents directed to production of cells
JP2010518361A (ja) 2007-01-23 2010-05-27 レキシコン ファーマシューティカルズ, インコーポレイテッド 新規の遺伝子破壊、組成物、およびそれに関連する方法
WO2008147481A1 (en) * 2007-02-09 2008-12-04 Northeastern University Precision-guided nanoparticle systems for drug delivery
US20080299182A1 (en) 2007-03-01 2008-12-04 Shuyuan Zhang Methods and formulations for topical gene therapy
US20080312581A1 (en) 2007-06-06 2008-12-18 Biovaluation & Analysis, Inc. Peptosomes for Use in Acoustically Mediated Intracellular Drug Delivery in vivo
US20080294089A1 (en) 2007-06-06 2008-11-27 Biovaluation & Analysis, Inc. Dendritic Polymers for Use in Acoustically Mediated Intracellular Drug Delivery in vivo
US20090018078A1 (en) 2007-07-09 2009-01-15 Vinod Labhasetwar Apoptosis-Modulating Protein Therapy for Proliferative Disorders and Nanoparticles Containing the Same
WO2009009591A2 (en) 2007-07-09 2009-01-15 Kansas State University Research Foundation Use of cells to facilitate targeted delivery of nanoparticle therapies
US20110038939A1 (en) 2007-07-16 2011-02-17 Northeastern University Therapeutic stable nanoparticles
WO2009023270A2 (en) 2007-08-15 2009-02-19 Amunix, Inc. Compositions and methods for modifying properties of biologically active polypeptides
AU2008296012A1 (en) 2007-09-07 2009-03-12 Gencia Corporation Mitochondrial compositions and uses thereof
EP2205225A4 (en) 2007-10-03 2013-09-18 Jncasr Bangalore INTRINSIC FLUORESCENCE CARBON NANOSPHERES AND PROCESS FOR PRODUCING THE SAME
PT2214646T (pt) 2007-10-05 2021-09-29 Univ Wayne State Dendrímeros para libertação sustentada de compostos
US20110045081A1 (en) * 2007-10-12 2011-02-24 Benedikt Steitz Magnetic, paramagnetic and/or superparamagnetic nanoparticles
DK2209496T3 (da) 2007-11-05 2019-08-05 Univ Vanderbilt Multifunktionelle nedbrydelige nanopartikler med kontrol over størrelse og funktioner
US20110274620A1 (en) 2007-11-05 2011-11-10 Harth Eva M Multifunctional degradable nanoparticles with control over size and functionalities
US20090148384A1 (en) 2007-12-10 2009-06-11 Fischer Katrin Functionalized, solid polymer nanoparticles comprising epothilones
US8563066B2 (en) 2007-12-17 2013-10-22 New World Pharmaceuticals, Llc Sustained release of nutrients in vivo
US20090169521A1 (en) 2007-12-31 2009-07-02 Technion Research & Development Foundation Ltd. Vascularized cardiac tissue and methods of producing and using same
EP2278999B1 (en) 2008-04-21 2025-01-29 Dompé farmaceutici S.p.A. Auris formulations for treating otic diseases and conditions
US8324333B2 (en) 2008-06-05 2012-12-04 Wisconsin Alumni Research Foundation Anionic charge-dynamic polymers for release of cationic agents
MX2011000545A (es) 2008-07-14 2011-02-24 Otonomy Inc Composiciones de liberacion controlada para la modulacion de apoptosis y metodos para el tratamiento de trastornos oticos.
US8496957B2 (en) 2008-07-21 2013-07-30 Otonomy, Inc Controlled release auris sensory cell modulator compositions and methods for the treatment of otic disorders
US10092580B2 (en) 2008-07-21 2018-10-09 Otonomy, Inc. Controlled-release otic structure modulating and innate immune system modulating compositions and methods for the treatment of otic disorders
US8399018B2 (en) 2008-07-21 2013-03-19 Otonomy, Inc. Controlled release ion channel modulator compositions and methods for the treatment of otic disorders
US8784870B2 (en) 2008-07-21 2014-07-22 Otonomy, Inc. Controlled release compositions for modulating free-radical induced damage and methods of use thereof
JP5529874B2 (ja) 2008-09-25 2014-06-25 インヴィーヴォ セラプーティクス コーポレーション 脊髄の損傷、炎症および免疫疾患に用いられる局所的に放出を制御しうる治療薬
CA2740125A1 (en) 2008-10-09 2010-04-15 Northeastern University Multifunctional self-assembling polymeric nanosystems
US9040087B2 (en) 2008-10-31 2015-05-26 The Invention Science Fund I, Llc Frozen compositions and methods for piercing a substrate
US8603495B2 (en) 2008-10-31 2013-12-10 The Invention Science Fund I, Llc Compositions and methods for biological remodeling with frozen particle compositions
US9060931B2 (en) 2008-10-31 2015-06-23 The Invention Science Fund I, Llc Compositions and methods for delivery of frozen particle adhesives
US8603494B2 (en) 2008-10-31 2013-12-10 The Invention Science Fund I, Llc Compositions and methods for administering compartmentalized frozen particles
US8613937B2 (en) 2008-10-31 2013-12-24 The Invention Science Fund I, Llc Compositions and methods for biological remodeling with frozen particle compositions
US8545856B2 (en) 2008-10-31 2013-10-01 The Invention Science Fund I, Llc Compositions and methods for delivery of frozen particle adhesives
US8849441B2 (en) 2008-10-31 2014-09-30 The Invention Science Fund I, Llc Systems, devices, and methods for making or administering frozen particles
US8545857B2 (en) 2008-10-31 2013-10-01 The Invention Science Fund I, Llc Compositions and methods for administering compartmentalized frozen particles
WO2010054264A1 (en) 2008-11-07 2010-05-14 Triact Therapeutics, Inc. Use of catecholic butane derivatives in cancer therapy
WO2010054326A2 (en) 2008-11-07 2010-05-14 The General Hospital Corporation C-terminal fragments of glucagon-like peptide-1 (glp-1)
US9308214B2 (en) * 2008-11-12 2016-04-12 Mitotech S.A. Method for moderately increasing the proton conductivity of biological membranes with the aid of mitochondria-targeted delocalized cations
AU2009330458B2 (en) 2008-12-22 2013-08-22 Otonomy, Inc. Controlled release auris sensory cell modulator compositions and methods for the treatment of otic disorders
US8273373B2 (en) 2008-12-30 2012-09-25 Case Western Reserve University Photocrosslinked biodegradable hydrogel
US20120027681A1 (en) 2009-03-11 2012-02-02 Northeastern University Low-Aspect Ratio Carbon Nanostructures
US8685538B2 (en) 2009-03-25 2014-04-01 Northeastern University Stable polyelectrolyte coated nanoparticles
EP2248903A1 (en) 2009-04-29 2010-11-10 Universitat Autònoma De Barcelona Methods and reagents for efficient and targeted gene transfer to monocytes and macrophages
AU2009347929A1 (en) 2009-06-12 2012-01-19 Amrita Vishwa Vidyapeetham University Targeted nano-photomedicines for photodynamic therapy of cancer
CA2765792C (en) 2009-06-17 2017-03-28 Ordway Research Institute, Inc. Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations and uses thereof
US20100331819A1 (en) 2009-06-24 2010-12-30 Abbott Cardiovascular Systems Inc. Drug Delivery System and Method of Treatment of Vascular Diseases Using Photodynamic Therapy
KR101609641B1 (ko) 2009-07-28 2016-04-07 삼성전자주식회사 무선통신 시스템에서 자동 이웃 관계 구성 및 최적화를 위한 장치 및 방법
EP2512522A4 (en) * 2009-12-16 2013-09-25 Brigham & Womens Hospital PARTICLES FOR ADMINISTRATION OF MULTIPLE AGENTS
US20110203013A1 (en) 2010-02-17 2011-08-18 Pioneer Hi Bred International Inc Delivering compositions of interest to plant cells
US20130196410A1 (en) 2010-03-05 2013-08-01 Alnylam Pharmaceuticals, Inc Compositions and methods for modifying the glycosylation pattern of a polypeptide
CN103079634B (zh) 2010-03-17 2016-01-20 苏州纳通生物纳米技术有限公司 可整合至施药器的内置式非语言指导设备
WO2011119901A1 (en) 2010-03-26 2011-09-29 Alnylam Pharmaceuticals, Inc. Gene amplification and transfection methods and reagents related thereto
CA2796464C (en) 2010-04-16 2021-08-03 Immune Disease Institute, Inc. Sustained polypeptide expression from synthetic, modified rnas and uses thereof
EP2576781B1 (en) 2010-06-04 2023-06-21 Hough Ear Institute Composition and method for inner ear sensory hair cell regeneration and replacement
US9284188B2 (en) 2010-09-03 2016-03-15 The Regents Of The University Of California Cytosolic delivery of materials with endosome-disrupting colloids
WO2012061466A2 (en) 2010-11-02 2012-05-10 The General Hospital Corporation Methods for treating steatotic disease
AR083705A1 (es) 2010-11-04 2013-03-13 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
CN103328038A (zh) 2010-12-01 2013-09-25 史拜诺莫度雷森公司 向神经解剖结构直接递送药剂
US9642925B2 (en) 2010-12-07 2017-05-09 Sanford Research/USD Magnetic nanoparticle formulations, methods for making such formulations, and methods for their use
WO2012092569A2 (en) 2010-12-31 2012-07-05 Selecta Biosciences, Inc. Compositions comprising immunostimulatory nucleic acids and related methods
EP2670426B1 (en) 2011-01-31 2017-05-10 The General Hospital Corporation Multimodal trail molecules and uses in cellular therapies
US20130136786A1 (en) 2011-02-10 2013-05-30 Sanford-Burnham Medical Research Institute Long non-coding rna spry4-it1 as a diagnostic and therapeutic agent
WO2012135848A2 (en) 2011-04-01 2012-10-04 Scott & White Healthcare Melatonin-based treatment and diagnosis of bile duct disease
US9140698B2 (en) 2011-04-06 2015-09-22 The Board Of Regents Of The University Of Texas System Modulating bacterial MAM polypeptides in pathogenic disease
US20120263793A1 (en) 2011-04-14 2012-10-18 Franco Vitaliano Bio-nano-plasmonic elements and platforms
WO2012142511A2 (en) 2011-04-15 2012-10-18 Md Matrix Health Llc Dba Md Matrix Health Inc Orthomolecular compositions and their use in stabilizing the extracellular matrix
AU2012249540B2 (en) 2011-04-29 2017-07-13 Selecta Biosciences, Inc. Tolerogenic synthetic nanocarriers to reduce immune responses to therapeutic proteins
EP2750662A4 (en) 2011-08-31 2015-06-24 Univ Georgia NANOPARTICLES OBTAINING APOPTOSIS
JP6356614B2 (ja) 2012-02-17 2018-07-11 ユニバーシティ・オブ・ジョージア・リサーチ・ファウンデイション・インコーポレイテッド 薬剤のミトコンドリア輸送のためのナノ粒子
US20150374714A1 (en) * 2013-02-11 2015-12-31 University Of Georgia Research Foundation, Inc. Generation of functional dendritic cells

Similar Documents

Publication Publication Date Title
JP2015513533A5 (enExample)
JP2013523703A5 (enExample)
JP2011136981A5 (enExample)
JP2013172734A5 (enExample)
JP2014132019A5 (enExample)
JP2016222689A5 (ja) 合成ペプチド及び乾燥粉末薬剤輸送システム
JP2016525888A5 (enExample)
JP2015514395A5 (enExample)
JP2010534684A5 (enExample)
ES2652643T3 (es) Péptidos terapéuticos y su uso contra la corea de Huntington
JP2010143932A5 (enExample)
JP2011168603A5 (enExample)
JP2014513484A5 (enExample)
JP2014519662A5 (enExample)
JP2010065037A5 (enExample)
JP2010265269A5 (enExample)
HK1205746A1 (en) Interleukin-10 polypeptide conjugates and their uses
JP2010088434A5 (enExample)
JP2014503607A5 (enExample)
JP2014224126A5 (enExample)
JP2012126742A5 (enExample)
JP2015038108A5 (enExample)
MX2016002937A (es) Vacuna oncologica.
JP2015533791A5 (enExample)
JP2012042477A5 (enExample)